Health Care and Pharmaceutical Industry in India is growing at a pace which even most progressive economists never anticipated. Pharmaceutical Industry is the “Sunrise Industry” in India even when the western world is under recession. Today almost 24000 manufacturers in India are producing pharmaceutical molecules in forms of tablets, capsules, syrups and injectable. However, the pharmacy retail market in India is largely unorganized. Currently there are about 1.2 million privately owned chemist and druggist stores in India, more than 80% of which are “Mom and Pop” shops. Statistics reveal that pharmacy retailing in India has a market size of over Rs 68,000 crore. Digital impact on Indian Pharmaceutical Retail is going to play a major role in terms of creating tremendous values in multiple ways. Specially digitalization will ensure speed, transparency, excellent pharmacy practice, good retail management, fair pricing and optimize profitability. Digital impact on Indian Pharmaceutical Retail is going to play a major role in terms of creating tremendous values in multiple ways. Specially digitalization will ensure speed, transparency, excellent pharmacy practice, good retail management, fair pricing and optimize profitability. Written by – Partha Banerjee
0 Comments
Health Care and Pharmaceutical Industry across the world is growing at a pace which even most progressive economists never anticipated. Pharmaceutical Industry is the “Sunrise Industry” even when entire world is under recession. Though there are more than 500000 pharmaceutical manufactures in the world but 250 players controls more than 90% of World’s Pharmaceutical Market (volume wise) that makes the World Pharmaceutical market more competitive. This allowed conservative experts to term the World Pharmaceutical Industry as most unorganized, fragmented and semi regulated. World Pharmaceutical Industry sustained and constantly grown primarily due to a) Huge sanitation & hygiene issues…so high prevalence of Invasive diseases in under developed and developing economies b) Increased incidence of life style diseases c) New inventions in Genetic and Degenerative areas Today World Pharmaceutical Industry started behaving with more maturity where even degenerative and genetic disorders contributing a fair percentage of the market. Western Drugs & Industrial houses (small & mid size companies) started exploring other emerging markets where the competition is low, turnaround is faster, return is much better and steady & regulations are fairly low. So, on pharmaceutical business front it is wise to create a basket with ‘short term, mid term & long-term’ revenue earners. Meaning a basket should have Invasive, Genetic, Degenerative & Life Style related molecules for better sustainability in this highly competitive world pharmaceutical market. It is important to notice that due to excessive financial pressure, weak marketing efforts and lack of innovative molecules small to medium size pharmaceutical companies fail to grow in major markets in developed economies. This picture is different when it comes to ‘under developed and developing economies’ as these markets still continuing to grow due various other factors especially due to imbalance in ‘demand and supply’ ratio. For small manufacturers to bring business success it is important for them to find out Niche areas and emerging markets for better sustainability. Written by – Partha Banerjee
Though an estimated US $ 100 Billion is spent annually for over 3 Million patients for treating end stage renal diseases globally, very little research is done. In recent years the areas of dialysis-related research is concentrated in the efficiency of the dialysis machines mainly funded by a few western players. India as a country is almost nonexistent in this field. A research oriented Dialysis facility in the area will not only cater to the deprived patient base of the region but can also generate significant patient data for pioneering analysis and research in the following untouched areas. These have immense commercial potential. The following seven areas calls for immediate research and that may not even attract huge investments to complete the research. 1. Real time monitoring of major electrolyte levels: 100% patients have muscle cramp and fatigue. It requires real time monitoring and measurement of major electrolytes. There are no machines available currently that monitors all the electrolytes at a real time. A small device that can be fitted to the dialysis machine to monitor and measure the electrolyte levels. 2. Oral Electrolyte formulation as per the monitored levels: Research is required to create one or multiple oral electrolyte formulation, which will be in three categories – mild, moderate and severe. That will ensure vast majority of patients coming out of a dialysis session without any fatigue or muscle cramp. 3. Control the level of Epotin by various methods: Erythropoietin is used to increase the Hemoglobin level. But the patients do get affected by the over use of Erythropoietin. A potential research is needed in this area to optimize the use of erythropoietin 4. Plumbing and Flow Dynamics reengineering: To reduce the risk of infections and contamination there is a tremendous requirement for research and reengineering with smart filtration and plumbing methods. 5. Compact Reverse Osmosis Unit: Normally RO plants are big. If we need to do a mobile clinic so that patients who cannot travel can undergo dialysis, a compact RO facility is required with high quality standards which can give better water quality than portable RO systems. A huge amount of engineering research is required for that. 6. Low cost highly efficient single-use dialyzer: The single use dialyzer cost should be brought down to $1 (US). We will have to work on the fibres/membrane. Is Polysulfone the right choice? The surface area, ultra filtration coefficient and absorption ability needs to be thoroughly researched. Furthermore, the ability and technique to replace the fibre membrane without replacing the cartridge holds the key. 7. Various other studies like optimum dosage calculation (pre, peri & post dialysis) for diabetic & cardiac patients. And various other researches on optimizations on medical management. A tremendous amount of research potential is awaited in these areas. Written by – Partha Banerjee
|